TITLE

Reply to “Small Dense Low-Density Lipoprotein Could Be Used as a Therapeutic Marker for Treatment in Patients With Acute Coronary Syndrome”

AUTHOR(S)
Rahsepar, Amir Ali; Alavi, Maryam-sadat; Ghayour-Mobarhan, Majid; Ferns, Gordon
PUB. DATE
November 2013
SOURCE
Angiology;Nov2013, Vol. 64 Issue 8, p645
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the authors' comments in response to the article "Small dense low-density lipoprotein could be used as a therapeutic marker of treatment in patients with acute coronary syndrome" published in a previous issue. The authors say that their study shows higher levels of small-dense low-density lipoprotein (sdLDL) in acute coronary syndrome (ACS) patients than in healthy participants.
ACCESSION #
90483748

 

Related Articles

  • Changes in Small Dense Low-Density Lipoprotein Levels Following Acute Coronary Syndrome. Emadzadeh, Mahdi Reza; Alavi, Maryam-Sadat; Soukhtanloo, Mohammad; Mohammadpour, Toktam; Rahsepar, Amir Ali; Tavallaie, Shima; Khojasteh, Roshanak; Paydar, Roghayeh; Amini, Maral; Parizadeh, Seyyed Mohammad Reza; Akhlaghi, Saeed; Ghayour-Mobarhan, Majid; Ferns, Gordon A. // Angiology;Apr2013, Vol. 64 Issue 3, p216 

    Low-density lipoprotein (LDL), especially small dense LDL (sdLDL), plays a role in atherogenesis. We compared baseline sdLDL levels between healthy controls and patients with acute coronary syndrome (ACS). Blood samples were taken from patients diagnosed with myocardial infarction ([MI]...

  • Small Dense Low-Density Lipoprotein Could Be Used as a Therapeutic Marker for Treatment in Patients With Acute Coronary Syndrome. Yıldırım, Erkan; Bugan, Barıs; Celik, Murat; Yuksel, Uygar Cagdas; Yalçınkaya, Emre // Angiology;Nov2013, Vol. 64 Issue 8, p644 

    The article presents the authors' comments on the study "Changes in small dense low-density lipoprotein levels following acute coronary syndrome," by M.R. Emadzadeh and colleagues. The study compares the baseline small dense low-density lipoprotein (sdLDL) levels in patients with acute coronary...

  • Correlation of Oxidized Low-Density Lipoprotein and C-Reactive Protein in Patients with Coronary Artery Disease. Huang, Yuli; Wu, Yanxian; Hu, Yunzhao // Cell Biochemistry & Biophysics;Mar2013, Vol. 65 Issue 2, p285 

    A letter to the editor about the correlation of oxidized low-density lipoprotein and C-reactive protein in patients with acute coronary syndrome (ACS) is presented.

  • Serum CXCL16 as a Novel Marker of Renal Injury in Type 2 Diabetes Mellitus. Zhao, Leping; Wu, Fan; Jin, Leigang; Lu, Tingting; Yang, Lihui; Pan, Xuebo; Shao, Chuanfeng; Li, Xiaokun; Lin, Zhuofeng // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: Soluble C-X-C chemokine ligand 16 (CXCL16), a scavenger receptor for oxidized low density lipoprotein, has been shown to promote atherogenic effects in vivo and to predict long-term mortality in acute coronary syndrome. The aim of this study was to explore the association of...

  • Low-Density Lipoprotein Particle Size as an Independent Predictor of Glycated Low-Density Lipoprotein Level. Matsui, Hideo; Okumura, Kenji; Toki, Yukio; Hayakawa, Tetsuo // Diabetes Care;Jul99, Vol. 22 Issue 7, p1220 

    Offers information on a study on the relation between glycated low-density lipoprotein (LDL) level and LDL particle size as linked to the development of atherosclerosis in patients with diabetes. Methodology; Findings; Conclusions.

  • Elevated Levels of Oxidized Low-Density Lipoprotein Correlate Positively with C-Reactive Protein in Patients with Acute Coronary Syndrome. Zhang, Ya-chen; Wei, Jing-jing; Wang, Fei; Chen, Man-tian; Zhang, Mao-zhen // Cell Biochemistry & Biophysics;Mar2012, Vol. 62 Issue 2, p365 

    The relationship between oxidized low-density lipoprotein (Ox-LDL) and C-reactive protein (CRP) in patients with acute coronary syndrome (ACS) is unknown. We, therefore, measured serum levels of Ox-LDL and high-sensitivity (hs)-CRP in 90 ACS patients, 45 stable angina pectoris (SAP) patients,...

  • Anthera'a Varespladib Fails: Biomarkers, Outcomes Differ. Morrison, Trista // BioWorld Today;3/13/2012, Vol. 23 Issue 49, p1 

    The article reports that the Phase III trial of Hayward, California-based Anthera Pharmaceuticals Inc. for its varespladib, an sPLA2 inhibitor it licensed from Eli Lilly and Co. and Shionogi & Co. Ltd., was halted for futility. It reveals that the drug reduced 15% of low-density lipoprotein...

  • Oxidized Low-Density Lipoprotein and C-Reactive Protein Have Combined Utility for Better Predicting Prognosis After Acute Coronary Syndrome. Zhang, Ya-chen; Tang, Yong; Chen, Yu; Huang, Xiao-hong; Zhang, Min; Chen, Jian; Sun, Ying-gang; Li, Yi-gang // Cell Biochemistry & Biophysics;Mar2014, Vol. 68 Issue 2, p379 

    It has been shown that the elevated concentrations of oxidized low-density lipoprotein (Ox-LDL) or high-sensitivity C-reactive protein (hs-CRP) are predictive of future cardiovascular events for acute coronary syndrome (ACS) patients. But, the combined value of Ox-LDL and hs-CRP for predicting...

  • Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Laczik, R.; Szodoray, P.; Veres, K.; Szomják, E.; Csípő, I.; Sipka Jr., S.; Shoenfeld, Y.; Szekanecz, Z.; Soltész, P. // Lupus;Jun2011, Vol. 20 Issue 7, p730 

    Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics